Provided is a cancer antigen peptide that does not require HLA type inspection, that is not restricted to patients having a specific HLA type, and that can be administered to a wide range of cancer patients as a cancer peptide vaccine. A peptide having 5 linked CTL epitopes, the peptide being obtained by linking, via a linker, 5 CTL epitope peptides selected from a group of CTL epitope peptides reported to be capable of CTL induction and derived from tumor antigen molecules.本發明提供一種癌抗原肽,其可在無需HLA型檢查,且不限定於具有特定之HLA型之患者之情況下,作為癌胜肽疫苗而投予廣泛之癌症患者。本發明之CTL抗原決定部位5連結肽係經由連結子將選自報告具有CTL誘導能力之源自腫瘤抗原分子之CTL抗原決定部位肽群中之5個CTL抗原決定部位肽連結而獲得者。
